

Contents

Foreword	xiii
Preface	xv
Contributors	xvii
1 Adenoviruses	1
<i>Kate Relph, Kevin J. Harrington, Alan Melcher and Hardev S. Pandha</i>	
1.1 Introduction	1
1.2 Viral structure and life cycle	1
1.3 Adenoviral vectors	5
1.4 Targeting adenoviral vectors	6
1.5 Clinical applications of adenoviral gene therapy	7
1.6 Adenoviral vectors for immunotherapy	7
1.7 Adenoviral vectors for suicide gene therapy	10
1.8 Adenoviral vectors for gene replacement therapy	11
1.9 Oncolytic adenoviral therapy	12
1.10 Adverse outcomes of adenoviral gene therapy	13
1.11 Summary	13
References	14
2 Application of HSV-1 vectors to the treatment of cancer	19
<i>Paola Grandi, Kiflai Bein, Costas G. Hadjipanayis, Darren Wolfe, Xandra O. Breakefield and Joseph C. Glorioso</i>	
2.1 Introduction	19
2.2 Basic biology of HSV	19
2.3 Replication competent or oncolytic vectors	24
2.4 Replication defective vectors	28
2.5 Amplicons	30
2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy	32

2.7	Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy	36
2.8	Summary and conclusions	42
	Acknowledgements	42
	References	42
3	Adeno-associated virus	55
	<i>Selvarangan Ponnazhagan</i>	
3.1	Introduction	55
3.2	Biology and life cycle of AAV	55
3.3	AAV serotypes	57
3.4	Production of recombinant AAV	57
3.5	Gene therapy for cancer treatment	57
3.6	Anti-oncogenic properties of AAV	58
3.7	Molecular chemotherapy studies with rAAV	59
3.8	AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy	59
3.9	rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses	60
3.10	rAAV vectors can be used to initiate immune responses	61
3.11	Altering AAV tropism for tumour-specific delivery	62
3.12	Clinical trials involving rAAV	62
3.13	Conclusion	63
	Acknowledgements	63
	References	63
4	Retroviruses	69
	<i>Simon Chowdhury and Yasuhiro Ikeda</i>	
4.1	Introduction	69
4.2	Structure of retroviral particles	69
4.3	Retroviral genome	69
4.4	Retroviral life cycle	70
4.5	Retroviral vectors	71
4.6	Safety of retroviral vectors: insertional mutagenesis	72
4.7	Gene therapy of X-linked SCID	72
4.8	Retroviral cancer gene therapy	75
4.9	Immunomodulatory approaches	78
4.10	Conclusions	79
	References	80
5	Lentiviral vectors for cancer gene therapy	83
	<i>Antonia Follenzi and Elisa Vigna</i>	
5.1	Development of lentiviral vectors (LV)	83
5.2	Targeting of transgene expression	85
5.3	Host immune responses to LV and their transgene	86
5.4	Transgenesis	87
5.5	Haematopoietic stem cell gene transfer	87

5.6	Cancer treatment by LV	89
5.7	Approved clinical trials using LV	91
5.8	Conclusions	91
	References	91
6	Poxviruses as immunomodulatory cancer therapeutics	95
	<i>Kevin J. Harrington, Hardev S. Pandha and Richard G. Vile</i>	
6.1	Introduction	95
6.2	General features of poxvirus structure and biology	95
6.3	Clinically applicable poxviruses	97
6.4	Poxviruses as potential cancer therapeutics	99
6.5	Clinical experience with poxviruses	102
6.6	Conclusions	110
	References	110
7	Oncolytic herpes simplex viruses	115
	<i>Guy R. Simpson and Robert S. Coffin</i>	
7.1	Introduction	115
7.2	Herpes simplex virology	115
7.3	Properties of HSV relevant to oncolytic virus therapy	117
7.4	Mutations giving tumour-selective replication	118
7.5	Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG)	125
7.6	Prodrug activation therapy and oncolytic HSV	126
7.7	Combination of oncolytic HSV with immunomodulatory gene expression	127
7.8	Combination of conventional therapies with oncolytic HSV	128
7.9	Summary	129
	Acknowledgement	130
	References	130
8	Selective tumour cell cytotoxicity by reoviridae – preclinical evidence and clinical trial results	139
	<i>Laura Vidal, Matt Coffey and Johann de Bono</i>	
8.1	Introduction	139
8.2	Reovirus structure	139
8.3	Reovirus replication	140
8.4	Reovirus and human infection	141
8.5	Oncolytic activity	142
8.6	Mechanism of reovirus-induced cytotoxicity	145
8.7	Preclinical experience	145
8.8	Immunogenicity	146
8.9	Clinical experience	146
8.10	Conclusions	147
	References	148
9	Oncolytic vaccinia	151
	<i>M. Firdos Ziauddin and David L. Bartlett</i>	
9.1	Introduction	151

9.2	Biology of vaccinia virus	151
9.3	Tumour selectivity and antitumour effect	153
9.4	Improving antitumour effects through bystander effects	160
9.5	Immune response to vaccinia and vaccinia immune evasion strategies	161
9.6	Virus-driven antitumour immune response	163
9.7	Imaging	164
9.8	Current and potential clinical applications	165
	References	166
10	Newcastle Disease virus: a promising vector for viral therapy of cancer	171
	<i>Volker Schirrmacher and Philippe Fournier</i>	
10.1	Introduction	171
10.2	Structure, taxonomy, pathogenicity and oncolytic properties of NDV	171
10.3	Human application and safety	172
10.4	Tumour-selective replication of NDV	174
10.5	Virally based cancer immunotherapy and danger signals	174
10.6	NDV: a danger signal inducing vector	175
10.7	The human cancer vaccine ATV-NDV	176
10.8	Pre-existing antitumour memory T cells from cancer patients and their activation by antitumour vaccination with ATV-NDV	177
10.9	Clinical trials of antitumour vaccination with ATV-NDV	177
10.10	NDV-specific recombinant bispecific antibodies to augment antitumour immune responses	179
10.11	NDV-binding bispecific fusion proteins to improve cancer specific virus targeting	180
10.12	Recombinant NDV as a new vector for vaccination and gene therapy	180
10.13	Conclusion	181
	References	182
11	Vesicular stomatitis virus	187
	<i>John Bell, Kelly Parato and Harold Atkins</i>	
11.1	Introduction	187
11.2	VSV: genomic organization and life cycle	187
11.3	Host range and pathogenesis of VSV infection	188
11.4	Control of VSV infection by the innate type I interferon response	189
11.5	Cancer cells are insensitive to type I interferon	190
11.6	VSV preferentially replicates in and lyses tumour cells <i>in vitro</i>	190
11.7	VSV attenuation: enhanced tumour selectivity and therapeutic index	192
11.8	Engineered/recombinant VSV	192
11.9	VSV effectively eradicates tumours <i>in vivo</i>	193
11.10	VSV and the host immune response	194
11.11	Host immunity vs. therapeutic efficacy	195
11.12	VSV is a potent vaccine	195
11.13	Innate sensing of VSV and the antitumour response	196
11.14	So what is a good oncolytic virus?	197
11.15	Future challenges for VSV	198
	References	199

12	Measles as an oncolytic virus	205
	<i>Adele Fielding</i>	
12.1	Introduction	205
12.2	Measles virus and the consequences of natural infection	205
12.3	MV vaccine	206
12.4	MV genetics and engineering	206
12.5	MV receptors	207
12.6	Animal models for the study of MV pathogenesis and oncolysis	207
12.7	Oncolytic activity of MV	208
12.8	Mechanism of specificity	208
12.9	Targeting MV entry	209
12.10	Enhancing the oncolytic activity of MV	210
12.11	Interactions with the immune system	210
12.12	Potential specific toxicities of clinical use of replicating attenuated MV	211
12.13	Clinical trials	211
12.14	Conclusions	212
	References	212
13	Alphaviruses	217
	<i>Ryuya Yamanaka</i>	
13.1	Introduction	217
13.2	RNA viruses as gene expression vectors	218
13.3	The biology of alphaviruses	218
13.4	Heterologous gene expression using alphavirus vectors	220
13.5	Cancer gene therapy strategies using alphavirus vectors	221
13.6	Alphavirus vector development for gene therapy application	223
13.7	Conclusions	224
	References	225
14	Tumour-suppressor gene therapy	229
	<i>Bingliang Fang and Jack A. Roth</i>	
14.1	Tumour-suppressor genes	229
14.2	Use of tumour-suppressing genes for cancer therapy	231
14.3	Clinical trials of <i>p53</i> gene replacement	232
14.4	Tumour-suppressor gene therapy in multimodality anticancer treatment	233
14.5	Future prospects	235
	Acknowledgements	235
	References	236
15	RNA interference and dominant negative approaches	241
	<i>Charlotte Moss and Nick Lemoine</i>	
15.1	Introduction	241
15.2	Oligonucleotide agents	241
15.3	Mechanism of RNAi	242
15.4	RNAi and antisense compared	243

15.5	siRNA design	244
15.6	Off-target effects	244
15.7	Induction of innate immunity	246
15.8	Methods of delivery	247
15.9	Antisense	251
15.10	Dominant negative approaches	252
15.11	Research applications of siRNA	252
15.12	Therapeutic applications of siRNA	252
	References	253
16	Gene-directed enzyme prodrug therapy	255
	<i>Silke Schepelmann, Douglas Hedley, Lesley M. Ogilvie and Caroline J. Springer</i>	
16.1	Introduction	255
16.2	Enzyme-prodrug systems for GDEPT	255
16.3	Gene delivery vectors for GDEPT	262
16.4	Conclusions	268
	References	269
17	Immunomodulatory gene therapy	277
	<i>Denise Boulanger and Andrew Bateman</i>	
17.1	Introduction	277
17.2	Immunotherapy strategies using viral vectors	277
17.3	Viruses used as viral vectors in cancer immunotherapy	280
17.4	Clinical trials against specific TAA	283
17.5	Conclusions and future prospects	289
	References	290
18	Antiangiogenic gene delivery	295
	<i>Anita T. Tandle and Steven K. Libutti</i>	
18.1	Angiogenesis: role in tumour development and metastasis	295
18.2	Targeting tumour vasculature as an approach for cancer treatment	297
18.3	Viral vectors to deliver antiangiogenic gene products	299
18.4	Viral targeting	303
18.5	Concluding remarks	306
	References	306
19	Radiosensitization in viral gene therapy	313
	<i>Jula Veerapong, Kai A. Bickenbach and Ralph R. Weichselbaum</i>	
19.1	Introduction	313
19.2	Adenovirus	313
19.3	Adeno-associated viruses	314
19.4	Herpes simplex viruses	314
19.5	Enhancing the effect of radiation by delivering tumour suppressor genes	316
19.6	Virus-directed enzyme prodrug therapy	316

19.7	Conclusions	322
	References	324
20	Radioisotope delivery	327
	<i>Inge D.L. Peerlinck and Georges Vassaux</i>	
20.1	Introduction	327
20.2	History of iodine therapy	327
20.3	Genetic therapy	330
20.4	Conclusion	338
	References	338
21	Radioprotective gene therapy: current status and future goals	341
	<i>Joel S. Greenberger and Michael W. Epperly</i>	
21.1	Introduction	341
21.2	Organ-specific radiation protection: oral cavity/oropharynx	342
21.3	MnSOD-PL treatment reduces pulmonary irradiation damage	354
21.4	MnSOD-PL gene therapy down-modulates marrow cell migration to the lungs	357
21.5	MnSOD-PL systemic administration for radiation protection from TBI	358
21.6	Summary and future directions	359
	References	360
22	Chemoprotective gene delivery	377
	<i>Michael Milsom, Axel Schambach, David Williams and Christopher Baum</i>	
22.1	Introduction	377
22.2	The promise of chemoselection strategies	377
22.3	The limitations of chemoselection strategies	381
22.4	Which expression level of chemoprotective genes is appropriate?	384
22.5	Vector design to achieve optimal expression levels	385
22.6	Exploring side effects of continued transgene expression and insufficient chemoprotection	387
22.7	The future: inducible expression of drug resistance genes	388
	Acknowledgements	389
	References	389
	Index	393